Selectivity Preparation Status Approval NCT Number
JAK1/JAK2i Baricitinib Approved Rheumatoid arthritis
CTP-543 II, III Alopecia Areata NCT05041803; NCT03898479; NCT04784533; NCT03941548; NCT03811912; NCT04797650; NCT04518995
PF06700841 II Systemic Lupus Erythematosus NCT03845517;
II Atopic Dermatitis NCT03903822
II Psoriatic Arthritis; Alopecia Areata NCT03963401
II Chronic Plaque; Psoriasis; Psoriasis NCT02969018; NCT03850483
II Crohn’s Disease; Ulcerative Colitis NCT03395184; NCT02958865
II Acne Inverse NCT04092452
II Alopecia Areata; Cicatricial Alopecia NCT02974868; NCT05076006
II Active Non-segmental Vitiligo NCT03715829
Ruxolitinib
Approved
Polycythemia vera, intermediate-high risk myelofibrosis
Upadacitinib Approved Rheumatoid Arthritis
JAK1/JAK3i ATI-501 II Alopecia; Areata Alopecia; Universalis Alopecia; Totalis; NCT03759340; NCT03594227
ATI-502 II Alopecia Areata; Alopecia; Universalis Alopecia; Totalis; Atopic Dermatitis NCT03759340; NCT03585296
Tofacitinib
approved
Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis